Abstract: The present inventive technology is directed the novel therapeutic application of muropeptides as class of novel ATP synthase agonists. In particular, the invention includes systems, methods and compositions for the use of muropeptides as novel ATP synthase agonists, and their use as a therapeutic agents to treat diseases and conditions that involve abnormal ATP synthase and mitochondrial activities.

Abstract: In one embodiment, the invention relates to the use of ferric enterobactin (Fe Ent), and/or Fe-Ent analogs as a therapeutic agent to treat iron deficiency and anemia. In a preferred embodiment, Fe-Ent and/or Fe-Ent analogs may be delivered to a host organism, such as a human subject to treat an iron-related disease condition or other anemia. In alternative embodiments, delivered to a host organism, such as a human subject to promote production or red blood cells. In such an embodiment, Ent and/or Ent analogs may be delivered to a human subject in need thereof through a pharmaceutical composition or through a genetically engineered bacteria, such as a probiotic organism configured to express Ent.